NEW:

Evidence

Click below to explore the latest additions to VERI


No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: B - Late Trials Bristol-Myers Squibb Press Release - Today lisocabtagene maraleucel Sensitive: B - Late Trials Bristol-Myers Squibb Press Release - Today
PD-L1 expression PD-L1 expression	Cervical Cancer Cervical Cancer	pembrolizumab Sensitive: A2 - Guideline Precision Oncology News - 2 days pembrolizumab Sensitive: A2 - Guideline Precision Oncology News - 2 days
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	pembrolizumab Sensitive: A1 - Approval FDA - 2 days pembrolizumab Sensitive: A1 - Approval FDA - 2 days
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval Regeneron Pharmaceuticals Press Release - 2 days cemiplimab Sensitive: A1 - Approval Regeneron Pharmaceuticals Press Release - 2 days
HER-2 positive HER-2 positive	Solid Tumor Solid Tumor	CT-0508 Sensitive: D – Preclinical J Transl Med - 3 days CT-0508 Sensitive: D – Preclinical J Transl Med - 3 days
HER-2 amplification HER-2 amplification	Cholangiocarcinoma Cholangiocarcinoma	pembrolizumab + lenvatinib + pyrotinib Sensitive: C4 – Case Studies World J Surg Oncol - 4 days pembrolizumab + lenvatinib + pyrotinib Sensitive: C4 – Case Studies World J Surg Oncol - 4 days
SMARCA4 deletion SMARCA4 deletion	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: C4 – Case Studies Front Immunol - 4 days nivolumab Sensitive: C4 – Case Studies Front Immunol - 4 days
PIK3CA mutation + AKT mutation + PTEN mutation PIK3CA mutation + AKT mutation + PTEN mutation	Solid Tumor Solid Tumor	ARQ 751 Sensitive: C3 – Early Trials Cancer - 4 days ARQ 751 Sensitive: C3 – Early Trials Cancer - 4 days
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	dostarlimab Sensitive: B - Late Trials N Engl J Med - 4 days dostarlimab Sensitive: B - Late Trials N Engl J Med - 4 days
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: B - Late Trials Novartis Press Release - 4 days ribociclib Sensitive: B - Late Trials Novartis Press Release - 4 days
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: A1 - Approval Ono Pharmaceuticals Press Release - 4 days nivolumab Sensitive: A1 - Approval Ono Pharmaceuticals Press Release - 4 days
HER-2 underexpression HER-2 underexpression	Breast Cancer Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval Daiichi Sankyo Press Release - 4 days fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval Daiichi Sankyo Press Release - 4 days